Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Yang, Yong, Wang, Ying, Liu, Xin, He, Xia, Zhang, Li-Ling, Wu, Gang, Qu, Bao-Lin, Qian, Li-Ting, Hou, Xiao-Rong, Zhang, Fu-Quan, Qiao, Xue-Ying, Wang, Hua, Li, Gao-Feng, Zhu, Yuan, Cao, Jian-Zhong, Wu, Jun-Xin, Wu, Tao, Zhu, Su-Yu, Shi, Mei, Xu, Li-Ming, Su, Hang, Song, Yu-Qin, Zhu, Jun, Zhang, Yu-Jing, Huang, Hui-Qiang, Hu, Chen, Qi, Shu-Nan, Li, Ye-Xiong
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8179849/
https://ncbi.nlm.nih.gov/pubmed/32943751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01042-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados